Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
May 14, 2020 at 04:44 pm EDT
Share
Inspyr Therapeutics, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 609,000 compared to USD 724,000 a year ago. Net loss was USD 934,000 compared to USD 12,000 a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.22 a year ago.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 